Haima
2 known investors
Haima Therapeutics is a pre-clinical stage biopharma company developing cell-inspired therapies for bleeding and blood-related diseases, with an initial focus on platelet-inspired treatments for active bleeding and bleeding risks from trauma, surgery, thrombocytopenia, and rare bleeding disorders. Its lead technology, SynthoPlate, is a fully-synthetic hemostatic agent that acts at the injury site to amplify the body's natural clotting mechanisms.
BiotechMedical Devices
Founders & leadership
MB
Michael BruckmanCEO
MN
Matthew NealCMO
CP
Christa PawlowskiCOO and EVP of R&D
AS
Anirban Sen GuptaCTO
TP
Timothy PeluraExecutive Chair